Sponsored Content
- Sponsored Content
Accelerating Viral Clearance Studies: A Co-Virus Spike Approach
BPI Contributor
November 9, 2023
20 Min View
Date: Nov 9, 2023
Duration: 20 Min
Want to watch this webinar?
Complete activation for full access.
Already have an account?
Sponsored by Charles River Laboratories
This webcast features: Sandra Meier, Viral Clearance R&D Scientist, Charles River Laboratories.
To determine the safety of biologics, the potential of the manufacturing process to inactivate and/or remove potential viral contaminants is addressed. Therefore, starting material is typically spiked with a single virus solution and then subjected to the removal/inactivation procedure.
For significantly saving resources such as material, time, and manpower, a co-virus spike approach using Murine Leukemia Virus (MuLV) and Minute Virus of Mice (MVM) was tested for its applicability in viral clearance studies.
In this webinar, Charles River will address:
The possibility to determine the virus specific clearance capacity of a manufacturing step even under co-spike conditions by quantifying each virus separately.
The comparison of log10 reduction factors obtained by chromatography and virus retentive filtration using single virus spike versus co-virus spike approach.
The benefits in terms of saving time and resources when applying the MuLV-MVM co-spike in your viral clearance study:
Up to 50% savings in chromatography columns, virus retentive filters, and process intermediates.
Up to 50% time reduction for viral spiking runs.
Up to 45% cost savings in process performance costs when CRL performs the process.
Thank you for your interest in this webcast. You may submit your request to view the webcast, and you will receive a confirmation email with log-in details.
About the Author
You May Also Like
Sponsored Content
Jun 5 - Jun 6, 2024
Jun 5 - Jun 6, 2024
Exploit Advances in Exosomes to Improve Efficiencies in Drug Delivery: Connect with senior-level executives and scientists who will share new data and novel case studies on advancing EV products through clinical stage towards commercialization
Learn More
